Global Fusion Biopsy Market 2023-2030

Global Fusion Biopsy Market 2023-2030

Global Fusion biopsy Market Size, Share & Trends Analysis Report by Biopsy Route (Transrectal and Transperineal), and by End User (Hospitals, Diagnostic Centers and Ambulatory Care Centers), Forecast Period (2023-2030)

The global fusion biopsy market is anticipated to grow at a CAGR of 8.4% during the forecast period (2023-2030). Fusion biopsy is a minimally invasive procedure that uses a combination of magnetic resonance imaging (MRI) and ultrasound technology to guide the biopsy of suspicious areas in the prostate gland. This procedure is used to diagnose prostate cancer, which is the most common cancer among men worldwide. The major players in the market are focusing on introducing new technology in the market for better advanced medical treatment and diagnosis. For instance, in July 2023, FUJIFILM Healthcare Europe unveiled the ARIETTA 65 IntuitiveFusion, a diagnostic ultrasound system with dedicated prostate fusion imaging to help urologists streamline biopsies. FUJIFILM Healthcare Europe launched the ARIETTA 65 IntuitiveFusion at the recent European Association of Urology (EAU) congress in Amsterdam, the Netherlands. This compact system is powered by ultrasound unique engine and integrated fusion software to allow stereotactic navigation of targeted prostate biopsies.

Segmental Outlook

The global fusion biopsy market is segmented on the biopsy route, and end user. Based on the biopsy route, the market is sub-segmented into transrectal and transperineal. Based on the end user, the market is sub-segmented into hospitals, diagnostic centers and ambulatory care centers. Among the end-user, the hospital sub-segment is anticipated to hold a considerable share of the market, owing to high purchasing power. The average unit price of a fusion biopsy system is high, making it unaffordable for private diagnostic centers.

The Transrectal Sub-Segment is Anticipated to Hold a Considerable Share of the Global Fusion biopsy Market

Among the biopsy route, the transrectal sub-segment is expected to hold a considerable share of the global Fusion biopsy market. This segmental growth is attributed to factor includes, the process performed through the rectum. This is the most common type of fusion biopsy, as it allows for easy access to the prostate gland. Also, it has lower risk of infection and shorter procedure time which make it more suitable to use. It lead to increase in strategic initiatives for this Biopsy Route and market players are focusing on developing new and improved products. For instance, in January 2023, Fortis Hospital, Bannerghatta Road announced the launch of BK ultrasound MRI Fusion Biopsy solution, a game changer in Prostate cancer diagnosis and treatment. Robot-aided surgery is a minimally invasive procedure which allows surgeons to have better vision, precision, and control while performing the surgeries. Other benefits include decreased pain, fewer post-operative infections and less scarring. Recovery is rapid, with minimal hospital stay, faster mobilization and rehabilitation. Reducing the chance of infection makes it an ideal procedure for people with diabetes and other co-morbidities.

Regional Outlook

The global fusion biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to hold a prominent share of the market across the globe, owing to rising prevalence of prostate cancer in the region. According to Prostate Cancer UK, more than 52,000 men are diagnosed with prostate cancer every year on average - that is 144 men every day. Every 45 minutes one man dies from prostate cancer - that is more than 12,000 men every year.

The North America Region is Expected to Grow at a Significant CAGR in the Global Fusion biopsy Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to new product launches, expansion of already existing business, rising awareness of prostate cancer, increasing population base, and rising disposable income levels in the region. According to National Cancer Institute, the rate of new cases of prostate cancer was 113.4 per 100,000 men per year. The death rate was 18.8 per 100,000 men per year. Approximately 12.9 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2017- 2019 data. In 2020, there were an estimated 3,343,976 men living with prostate cancer in the United States. Hence, the market players are continuously introducing new product for cancer treatment in the region. For instance, in June 2023, Hoag is giving men with localized prostate cancer an additional treatment option in the battle against disease with the introduction of Focal One, a non-invasive robotic High Intensity Focused Ultrasound (HIFU) technology. An advanced technology that precisely targets cancerous prostate tissue, HIFU allows urologic surgeons to ablate, or destroy, just the diseased portion of the prostate. The result is a cancer treatment without many of the side effects that come with treating the entire prostate, including urinary and erectile side effects.

Market Players Outlook

The major companies serving the fusion biopsy market include Eigen Health, ESAOTE SpA, Focal Healthcare, GeoScan Medical, Hitachi Ltd., KOELIS, Koninklijke Philips N.V., MedCom, UC-Care Medical Systems Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In August 2022, Promaxo, Inc. announced it has entered into research collaborations with leading European university hospitals, Imperial College London and University Hospital Tuebingen Germany, for MR guided prostate interventions. In collaboration with Imperial College London, Promaxo received a grant and entered into a research agreement for a clinical study comparing Promaxo’s portable MRI and TRUS-Fusion biopsy to assess for accuracy in prostate cancer detection.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global fusion biopsy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.